TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 will be available from January 2023. […]
News
29/11/2022
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
Our news
News
News
16/01/2023
Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
> READ
Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
> READ
News
14/05/2024
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
> READ
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
> READ
> See all news